hydralazine has been researched along with Diabetic Nephropathies in 27 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare the effects of captopril with more conventional drugs on proteinuria and progression of renal disease, we conducted a prospective, 18-month study in 42 proteinuric (> 500 mg/day) NIDDM and, for comparison, in 31 nondiabetic patients with a variety of renal diseases (NDRD)." | 9.08 | Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 7.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| " To compare the effects of captopril with more conventional drugs on proteinuria and progression of renal disease, we conducted a prospective, 18-month study in 42 proteinuric (> 500 mg/day) NIDDM and, for comparison, in 31 nondiabetic patients with a variety of renal diseases (NDRD)." | 5.08 | Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| " We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury." | 3.74 | Overexpression of angiotensinogen increases tubular apoptosis in diabetes. ( Brezniceanu, ML; Chan, JS; Chénier, I; Filep, JG; Ingelfinger, JR; Liu, F; Sachetelli, S; Wei, CC; Zhang, SL, 2008) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| "To evaluate the role of glomerular hypertension, glomerular hypertrophy, glomerular lipid deposition, and plasma cholesterol levels in diabetic glomerulopathy, Munich-Wistar rats received streptozocin and daily insulin injections and were assigned to one of three groups: untreated diabetic (DMC), hydralazine-treated diabetic (DMH), and enalapril-treated diabetic (DME)." | 3.68 | Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. ( Fujihara, CK; Padilha, RM; Zatz, R, 1992) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 3.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "Hydralazine is an antihypertensive agent and may act as a xanthine oxidase (XO) inhibitor to reduce uric acid levels in a mouse renal injury model." | 1.72 | Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Lee, HJ; Lin, SC, 2022) |
| "High body iron levels are found in type 2 diabetes mellitus (DM)." | 1.39 | Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat. ( Akahori, H; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Tsujino, T, 2013) |
| "Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice." | 1.35 | Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. ( Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009) |
| "Hydralazine treatment significantly blocked the development of mesangiolysis and microaneurysms, whereas tubulointerstitial injury was not prevented in these mice." | 1.35 | Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. ( Atkinson, MA; Campbell-Thompson, M; Connor, T; Croker, BP; Grant, MB; Hauswirth, WW; Heinig, M; Kosugi, T; Li, Q; Nakagawa, T; Nakayama, T; Segal, MS; Yuzawa, Y; Zhang, L, 2009) |
| "Prevention or retardation of diabetic nephropathy (DN) includes anti-hypertensive treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on the premises that these drugs have an added protective effect beyond their influence on BP." | 1.32 | Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. ( Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (22.22) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Leu, JG | 1 |
| Su, WH | 1 |
| Chen, YC | 1 |
| Liang, YJ | 1 |
| Chang, TT | 1 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Lin, SC | 1 |
| Lee, HJ | 1 |
| Chen, JW | 1 |
| Tong, ZJ | 1 |
| Kuo, CW | 1 |
| Yen, PC | 1 |
| Lin, CC | 1 |
| Tsai, MT | 1 |
| Lu, SH | 1 |
| Chang, YP | 1 |
| Liu, WS | 1 |
| Tsou, HH | 1 |
| Cheng, HW | 1 |
| Wang, HT | 1 |
| Yao, L | 2 |
| Wu, YT | 1 |
| Tian, GX | 1 |
| Xia, CQ | 1 |
| Zhang, F | 1 |
| Zhang, W | 1 |
| Matsumoto, M | 1 |
| Sasaki, N | 1 |
| Tsujino, T | 1 |
| Akahori, H | 1 |
| Naito, Y | 1 |
| Masuyama, T | 1 |
| Gangadhariah, MH | 1 |
| Luther, JM | 1 |
| Garcia, V | 1 |
| Paueksakon, P | 1 |
| Zhang, MZ | 2 |
| Hayward, SW | 1 |
| Love, HD | 1 |
| Falck, JR | 1 |
| Manthati, VL | 1 |
| Imig, JD | 1 |
| Schwartzman, ML | 1 |
| Zent, R | 1 |
| Capdevila, JH | 1 |
| Pozzi, A | 1 |
| Yoshida, S | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Imai, N | 1 |
| Yasuzaki, H | 1 |
| Nomura, K | 1 |
| Kiuchi, Y | 1 |
| Tamura, K | 1 |
| Ishigami, T | 1 |
| Hirawa, N | 1 |
| Toya, Y | 1 |
| Kitamura, H | 1 |
| Umemura, S | 1 |
| Kosugi, T | 1 |
| Heinig, M | 1 |
| Nakayama, T | 1 |
| Connor, T | 1 |
| Yuzawa, Y | 1 |
| Li, Q | 1 |
| Hauswirth, WW | 1 |
| Grant, MB | 1 |
| Croker, BP | 1 |
| Campbell-Thompson, M | 1 |
| Zhang, L | 1 |
| Atkinson, MA | 1 |
| Segal, MS | 1 |
| Nakagawa, T | 1 |
| Wang, S | 1 |
| Yang, S | 1 |
| Yang, H | 1 |
| Fan, X | 1 |
| Takahashi, T | 1 |
| Harris, RC | 1 |
| Nangaku, M | 1 |
| Miyata, T | 2 |
| Sada, T | 1 |
| Mizuno, M | 1 |
| Inagi, R | 1 |
| Ueda, Y | 1 |
| Ishikawa, N | 2 |
| Yuzawa, H | 1 |
| Koike, H | 1 |
| van Ypersele de Strihou, C | 1 |
| Kurokawa, K | 2 |
| Nagai, Y | 1 |
| Kobori, H | 1 |
| Miyata, K | 1 |
| Ozawa, Y | 1 |
| Miyatake, A | 1 |
| Yukimura, T | 1 |
| Shokoji, T | 1 |
| Kimura, S | 1 |
| Kiyomoto, H | 1 |
| Kohno, M | 1 |
| Abe, Y | 1 |
| Nishiyama, A | 1 |
| Liu, F | 1 |
| Brezniceanu, ML | 1 |
| Wei, CC | 1 |
| Chénier, I | 1 |
| Sachetelli, S | 1 |
| Zhang, SL | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Chan, JS | 1 |
| Liou, HH | 1 |
| Huang, TP | 1 |
| Campese, VM | 1 |
| Mahnensmith, RL | 1 |
| O'Brien, RC | 2 |
| Cooper, ME | 2 |
| Jerums, G | 2 |
| Doyle, AE | 2 |
| Tang, Z | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Fukui, M | 1 |
| Tomino, Y | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Mogensen, CE | 2 |
| Teschner, M | 1 |
| Schaefer, RM | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| Fujihara, CK | 1 |
| Padilha, RM | 1 |
| Zatz, R | 1 |
| Allen, TJ | 1 |
| Papazoglou, D | 1 |
| Clarke, BE | 1 |
| Baba, T | 1 |
| Sawicki, PT | 1 |
| Anderson, S | 1 |
| Rennke, HG | 1 |
| Garcia, DL | 1 |
| Brenner, BM | 1 |
| Mathiesen, ER | 1 |
| Parving, HH | 1 |
| Hommel, E | 1 |
| Vertes, V | 1 |
| Cangiano, JL | 1 |
| Berman, LB | 1 |
| Gould, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Delaying the Progression of Diabetic Nephropathy in Pima Indians[NCT00353600] | 25 participants (Anticipated) | Observational | 1994-08-19 | Completed | |||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
3 reviews available for hydralazine and Diabetic Nephropathies
| Article | Year |
|---|---|
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2004 |
Diabetic nephropathy: a comprehensive approach.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Clinical Protocols; Clinical Tria | 1993 |
[Nephropathy in type 1 diabetes mellitus. Current experimental and clinical aspects].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Dia | 1992 |
1 trial available for hydralazine and Diabetic Nephropathies
| Article | Year |
|---|---|
Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Ne | 1995 |
23 other studies available for hydralazine and Diabetic Nephropathies
| Article | Year |
|---|---|
Hydralazine attenuates renal inflammation in diabetic rats with ischemia/reperfusion acute kidney injury.
Topics: Acute Kidney Injury; Animals; Cells, Cultured; Coculture Techniques; Diabetes Mellitus, Experimental | 2021 |
Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy.
Topics: Allopurinol; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose | 2022 |
Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo.
Topics: Acetylcysteine; Acrolein; Animals; Carnosine; Cytokines; Diabetes Mellitus; Diabetic Nephropathies; | 2022 |
Acrolein Scavenger Hydralazine Prevents Streptozotocin-Induced Painful Diabetic Neuropathy and Spinal Neuroinflammation in Rats.
Topics: Acrolein; Animals; Diabetic Nephropathies; Drug Evaluation, Preclinical; Hydralazine; Male; Rats, Sp | 2017 |
Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic N | 2013 |
Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.
Topics: Animals; Collagen; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Diabetic Nephropathies; | 2015 |
Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihype | 2009 |
Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Diabetes Mellitus, Experimental | 2009 |
Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2012 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mel | 2003 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
Overexpression of angiotensinogen increases tubular apoptosis in diabetes.
Topics: Albuminuria; Angiotensinogen; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protei | 2008 |
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressu | 1993 |
Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Captopril; Catalase; Diabetes Mellitu | 1997 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Diabetes and hypertension.
Topics: Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Furosemide; Glomerular Filtration Rate; H | 1979 |
Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.
Topics: Adolescent; Adult; Albuminuria; Diabetic Nephropathies; Furosemide; Glomerular Filtration Rate; Huma | 1976 |
Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy.
Topics: Albuminuria; Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; | 1992 |
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Topics: Administration, Oral; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Melli | 1990 |
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat: are these effects specific for enalapril?
Topics: Albuminuria; Animals; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic N | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Converting enzyme-inhibition in diabetic nephropathy.
Topics: Albuminuria; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Therapy, Combination; Furosemid | 1989 |
Hypertension in end-stage renal disease.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Chronic | 1969 |